JP2013523814A - Ｆａａｈの調節薬として有用なオキサゾール誘導体 - Google Patents

Ｆａａｈの調節薬として有用なオキサゾール誘導体 Download PDF

Info

Publication number
JP2013523814A
JP2013523814A JP2013503806A JP2013503806A JP2013523814A JP 2013523814 A JP2013523814 A JP 2013523814A JP 2013503806 A JP2013503806 A JP 2013503806A JP 2013503806 A JP2013503806 A JP 2013503806A JP 2013523814 A JP2013523814 A JP 2013523814A
Authority
JP
Japan
Prior art keywords
alkyl
halo
substituted
mono
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013503806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523814A5 (enExample
Inventor
ヤン，ジキアン
ナンテルメ，フイリツプ・ジー
クリートソーラス，コンスタンテイン
ムーア，キース・ピー
シヤレン，エバン・フオスター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2013523814A publication Critical patent/JP2013523814A/ja
Publication of JP2013523814A5 publication Critical patent/JP2013523814A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013503806A 2010-04-08 2011-04-04 Ｆａａｈの調節薬として有用なオキサゾール誘導体 Pending JP2013523814A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32199210P 2010-04-08 2010-04-08
US61/321,992 2010-04-08
PCT/US2011/031040 WO2011126960A1 (en) 2010-04-08 2011-04-04 Oxazole derivatives useful as modulators of faah

Publications (2)

Publication Number Publication Date
JP2013523814A true JP2013523814A (ja) 2013-06-17
JP2013523814A5 JP2013523814A5 (enExample) 2014-05-22

Family

ID=44763231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013503806A Pending JP2013523814A (ja) 2010-04-08 2011-04-04 Ｆａａｈの調節薬として有用なオキサゾール誘導体

Country Status (8)

Country Link
US (1) US9193697B2 (enExample)
EP (1) EP2555772B1 (enExample)
JP (1) JP2013523814A (enExample)
CN (1) CN102917704A (enExample)
AU (1) AU2011238487B2 (enExample)
BR (1) BR112012023974A2 (enExample)
CA (1) CA2793900A1 (enExample)
WO (1) WO2011126960A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017079A1 (en) * 2008-08-04 2010-02-11 Merck & Co., Inc. Oxazole derivatives useful as inhibitors of faah
EP2560655B1 (en) 2010-04-21 2016-08-24 Merck Sharp & Dohme Corp. Substituted pyrimidines
WO2018145932A1 (en) 2017-02-08 2018-08-16 Bayer Cropscience Aktiengesellschaft Triazole derivatives and their use as fungicides
EP3580217A1 (en) 2017-02-08 2019-12-18 Bayer Aktiengesellschaft Triazolethione derivatives
EP3580218A1 (en) 2017-02-08 2019-12-18 Bayer CropScience Aktiengesellschaft Novel triazole derivatives
WO2018145921A1 (en) 2017-02-10 2018-08-16 Bayer Aktiengesellschaft Composition for controlling harmful microorganisms comprising 1 -(phenoxy-pyridinyl)-2-(1,2,4-triazol-1 -yl)-ethanol derivatives
IL271149B2 (en) * 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
WO2020020816A1 (en) 2018-07-26 2020-01-30 Bayer Aktiengesellschaft Novel triazole derivatives
CN110804048A (zh) * 2019-11-08 2020-02-18 暨南大学 恶唑酮类化合物及其应用、faah的正电子药物
CN114727977A (zh) 2019-11-19 2022-07-08 特维娜有限公司 化合物和化合物s1p1调节剂的制备方法
KR20250033421A (ko) * 2023-08-29 2025-03-10 인천대학교 산학협력단 옥사졸 유사체를 유효성분으로 포함하는 항노화 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071753A1 (fr) * 2007-09-13 2009-06-11 Ipsen Pharma S.A.S. Derives de 4-phenyl-l, 3-thiazoles et de 4-phenyl-l, 3-oxazoles comme ligands des recepteurs cannabinoides
JP2009538358A (ja) * 2006-05-26 2009-11-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
WO2009152025A1 (en) * 2008-06-11 2009-12-17 Merck & Co., Inc. Imidazole derivatives useful as inhibitors of faah
WO2010017079A1 (en) * 2008-08-04 2010-02-11 Merck & Co., Inc. Oxazole derivatives useful as inhibitors of faah
JP2013518110A (ja) * 2010-01-28 2013-05-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛および他の適応症の治療用の医薬組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009538358A (ja) * 2006-05-26 2009-11-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
WO2009071753A1 (fr) * 2007-09-13 2009-06-11 Ipsen Pharma S.A.S. Derives de 4-phenyl-l, 3-thiazoles et de 4-phenyl-l, 3-oxazoles comme ligands des recepteurs cannabinoides
WO2009152025A1 (en) * 2008-06-11 2009-12-17 Merck & Co., Inc. Imidazole derivatives useful as inhibitors of faah
WO2010017079A1 (en) * 2008-08-04 2010-02-11 Merck & Co., Inc. Oxazole derivatives useful as inhibitors of faah
JP2013518110A (ja) * 2010-01-28 2013-05-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛および他の適応症の治療用の医薬組成物

Also Published As

Publication number Publication date
WO2011126960A1 (en) 2011-10-13
AU2011238487A1 (en) 2012-09-13
EP2555772A1 (en) 2013-02-13
CN102917704A (zh) 2013-02-06
CA2793900A1 (en) 2011-10-13
BR112012023974A2 (pt) 2017-09-26
US9193697B2 (en) 2015-11-24
EP2555772B1 (en) 2017-01-11
AU2011238487B2 (en) 2015-10-01
EP2555772A4 (en) 2013-08-28
US20130018048A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
JP5698666B2 (ja) Ｆａａｈの阻害剤として有用なオキサゾール誘導体
JP5856606B2 (ja) Ｆａａｈの調節薬として有用なオキサゾール誘導体
JP2013523814A (ja) Ｆａａｈの調節薬として有用なオキサゾール誘導体
US20110021531A1 (en) Oxazole derivatives useful as inhibitors of faah
US8455528B2 (en) Imidazole derivatives useful as inhibitors of FAAH
JP2013525490A (ja) Ｆａａｈのモジュレータとして有用なアザインドール誘導体
JP5667093B2 (ja) Ｆａａｈの調節剤およびｆａａｈ造影剤として有用なイミダゾール誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140402

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160726

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170228